Contact Us
Drug Search Results
More Filters [+]

Olipudase alfa

Alternative Names: olipudase alfa, gz-402665, gz402665, gz 402665, xenpozyme
Latest Update: 2024-11-07
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Austria | Belgium | Brazil | Croatia | Czech | European Medicines Agency | Finland | France | Germany | Greece | Hungary | Iceland | Ireland | Israel | Italy | Japan | Latvia | Lithuania | Norway | Poland | Portugal | Romania | Slovakia | Slovenia | Spain | Sweden | United Arab Emirates | United Kingdom | United States

Approved Indications: None

Known Adverse Events: None

Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Olipudase alfa

Countries in Clinic: Belgium, Brazil, France, Germany, Italy, United Kingdom, United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Lipidoses|Niemann-Pick Disease, Type A|Niemann-Pick Disease, Type C|Niemann-Pick Diseases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
LTS13632

P2

Completed

Niemann-Pick Diseases|Niemann-Pick Disease, Type C|Niemann-Pick Disease, Type A|Lipidoses

2023-09-06

Recent News Events

Date

Type

Title

08/09/2024

News Article

 The Galien Foundation Announces 2024 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Product" and "Best Product for Rare/Orphan Diseases"

07/02/2024

News Article

 HLS Therapeutics Announces the Sale of its XENPOZYME® Royalty Interest to DRI Healthcare Trust

07/02/2024

News Article

 DRI Healthcare Trust Announces Acquisition of an Additional Royalty Interest in the Worldwide Sales of Xenpozyme® (olipudase alfa) for the Treatment of Acid Sphingomyelinase Deficiency

07/27/2023

News Article

 The Galien Foundation Announces 2023 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Product" and "Best Product for Rare/Orphan Diseases"

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions